These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26125137)

  • 1. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
    Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
    AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
    Prentoe J; Bukh J
    Front Immunol; 2018; 9():2146. PubMed ID: 30319614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
    Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
    Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A preliminary assessment of the clinical utility of measuring hepatitis C virus antibody to evaluate infection status].
    Long L; Liu Y; Duan Z; Xu Q; Shen T; Dou X; Zhuang H; Lu F
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):244-50. PubMed ID: 25173220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.
    Castelain S; Schnuriger A; François C; Nguyen-Khac E; Fournier C; Schmit JL; Capron D; Dubuisson J; Wychowski C; Thibault V; Duverlie G
    J Infect Dis; 2008 Aug; 198(3):332-5. PubMed ID: 18558868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection.
    Barrett L; Gallant M; Howley C; Ian Bowmer M; Hirsch G; Peltekian K; Grant M
    J Viral Hepat; 2011 Mar; 18(3):170-80. PubMed ID: 20497309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher dN/dS ratios in the HCV core gene, but not in the E1/HVR1 gene, are associated with human immunodeficiency virus-associated immunosuppression.
    Xu CH; Shen T; Zheng JJ; Tu J; Zhang WD; Lu FM
    Arch Virol; 2012 Nov; 157(11):2153-62. PubMed ID: 22825695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
    Vieyres G; Dubuisson J; Patel AH
    J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses.
    Palmer BA; Schmidt-Martin D; Dimitrova Z; Skums P; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Virol; 2015 Dec; 90(7):3318-29. PubMed ID: 26719263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.
    Ciuffreda D; Comte D; Cavassini M; Giostra E; Bühler L; Perruchoud M; Heim MH; Battegay M; Genné D; Mulhaupt B; Malinverni R; Oneta C; Bernasconi E; Monnat M; Cerny A; Chuard C; Borovicka J; Mentha G; Pascual M; Gonvers JJ; Pantaleo G; Dutoit V
    Eur J Immunol; 2008 Oct; 38(10):2665-77. PubMed ID: 18958874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
    Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
    J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
    Prentoe J; Serre SB; Ramirez S; Nicosia A; Gottwein JM; Bukh J
    J Virol; 2014 Feb; 88(3):1725-39. PubMed ID: 24257605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
    Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL
    J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization.
    Korenaga M; Hino K; Katoh Y; Yamaguchi Y; Okuda M; Yoshioka K; Okita K
    J Viral Hepat; 2001 Sep; 8(5):331-40. PubMed ID: 11555190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
    Pedersen J; Lundbo LF; Krarup H; Bukh J; Weis N
    J Med Virol; 2016 Oct; 88(10):1791-803. PubMed ID: 27027386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-free virion titer greatly differs between hepatitis C virus genotypes.
    Kimura Y; Hayashida K; Ishibashi H; Niho Y; Yanagi Y
    J Med Virol; 2000 May; 61(1):37-43. PubMed ID: 10745230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.
    Watanabe K; Yoshioka K; Ito H; Ishigami M; Takagi K; Utsunomiya S; Kobayashi M; Kishimoto H; Yano M; Kakumu S
    Virology; 1999 Nov; 264(1):153-8. PubMed ID: 10544140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.